reports
- Jonathan Moreland
CNMD CONMED CORPORATION
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
ZOM ZOMEDICA PHARMACEUTICALS CORP
EYE NATIONAL VISION HOLDINGS
CDLX CARDLYTICS INC
ISDR ISSUER DIRECT CORP.
FSK FS KKR CAPITAL CORP
GO GROCERY OUTLET HOLDING
FNWB FIRST NORTHWEST BANCORP
FOUR SHIFT4 PAYMENTS
HQL INC.
TLS TEKLA LIFE SCIENCES INVESTORS
TMCI TELOS
FLYW TREACE MED CONCEPTS INC
BGS FLYWIRE CORP
DCGO B&G FOODS
BHVN INC.
GRNT DOCGO INC
VSTS_w BIOHAVEN LTD
BHRB GRANITE RIDGE RESOURCES INC
VESTIS CORPORATION
BURKE HERBERT FINANCIAL SERVICES CORP
Home BancShares, Inc. Announces Adjustments to Management Team: Poised...
Home BancShares, Inc. Announces Adjustments to Management Team: Poised for the Future CONWAY, Ark., May 14, 2024 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB) (“Home” or “the Company”), and its wholly-owned subsidiary, Centennial Bank (“Centennial”), while celebrating twenty-five years as a bank, announce some adjustments to the management team, as they look towards the future. Stephen Tipton will assume the position of Chief Executive Officer of Centennial Bank, having served as Chief Operating Officer since 2015. In addition to the role of Chief Lending Officer, Kevin Hester ...
InspireMD Reports First Quarter 2024 Financial Results and Provides Bu...
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well as Dr. Willi...
Akoya Biosciences Reports First Quarter 2024 Financial Results
Akoya Biosciences Reports First Quarter 2024 Financial Results MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.Akoya the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scal...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside cha...
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate...
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a pe...
VICI Properties Inc. Announces $250 Million Mezzanine Loan Origination...
NEW YORK--(BUSINESS WIRE)-- VICI Properties Inc. (NYSE: VICI) (the “Company”, “VICI” or “VICI Properties”) announced today that it has originated a $250 million mezzanine loan (the “Mezzanine Loan”) as part of a $1.55 billion financing that also includes a single borrower group CMBS securitization (the “Great Wolf Loan”) for Great Wolf Resorts, Inc. (“Great Wolf”) through its VICI Experiential Credit Solutions strategy. The Great Wolf Loan will be collateralized by a portfolio of nine Great Wolf Lodge resorts with over 4,000 keys, approximately 695,000 square feet of indoor and outdoor waterpa...
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Resul...
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenu...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 ...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent cor...
Quest Resource Holding Corporation Reports First Quarter 2024 Financia...
Quest Resource Holding Corporation Reports First Quarter 2024 Financial Results Double-Digit Growth in Gross Profit Resulting from Business Expansion and Efficiency Gains Significant New Business Wins and Pipeline Growth Reflect Company’s Strong Value Proposition and Momentum Investor Conference Call & Webcast to be held at 5pm ET on Thursday, May 9, 2024 THE COLONY, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation (NASDAQ: QRHC) (“Quest”), a national leader in environmental waste and recycling services, today announced financial results for the first quarter ...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to En...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of lab...
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million...
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the n...
Establishment Labs Reports First Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook First quarter worldwide revenue of $37.2 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants® in the United States, which is expected in 2024. Gross...
Vintage Wine Announces Forbearance Agreement Extension with Lenders
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (the “Company”) today announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, 2024 (as amended, the “amended forbearance agreement”) to extend the forbearance period to June 4, 2024. The lenders have also agreed to defer the $10 million principal payment previously due at May 15, 2024 to June 17, 2024. Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, 2024, so lo...
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics to Present at Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will participate in ...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
Pacira BioSciences Reports First Quarter 2024 Financial Results and An...
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program -- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 Financial Highlights Total revenues of $167.1 millionNet product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°N...
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Cap...
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, Inc. (Na...
InspireMD to Report First Quarter 2024 Financial Results and Provide C...
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the i...
VPG Reports Fiscal 2024 First Quarter Results
VPG Reports Fiscal 2024 First Quarter Results MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024. First Fiscal Quarter Highlights: Revenues of $80.8 million decreased 9.1% from a year ago.Gross profit margin was 43.4%, as compared to 41.9% reported a year ago.Operating margin was 8.6%, as compared to 11.2% reported a year ago.Adjusted operating margin* was 10.0%, as compared to 11.4% reported a year a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.